Globus Medical reports recurring developments in musculoskeletal technology, including sales and earnings updates for its spine, orthopedic and enabling technology businesses. The company develops medical devices, instruments and computer-assisted systems used in musculoskeletal procedures and sells to hospitals, physicians and surgical centers in the United States and international markets.
Company news also covers US Spine demand, Enabling Technologies customer expansion, product pipeline execution, integration activity following completed NuVasive and Nevro transactions, preliminary sales guidance, earnings conference calls and board composition changes.
Globus Medical (NYSE: GMED) reported Q1 2026 results: worldwide net sales $759.9M (+27.0%; +25.5% constant currency) and GAAP net income $124.3M. GAAP diluted EPS was $0.90 and non-GAAP diluted EPS was $1.12. The company reaffirmed 2026 revenue guide of $3.18B–$3.22B and raised non-GAAP EPS guidance to $4.70–$4.80. Management cited organic growth, Nevro acquisition contribution, margin expansion from operating leverage, and integration progress.
Globus Medical (NYSE:GMED) will announce first quarter results for the period ended March 31, 2026 after market close on Thursday, May 7, 2026.
The company will host a teleconference at 4:30 p.m. Eastern Time the same day, available via live webcast on the Globus Medical Investors page; telephone participation requires advance registration. An audio archive will be posted afterward.
Globus Medical (NYSE:GMED) announced that Director John A. DeFord, PhD stepped down from the Board effective March 23, 2026, and will not seek re-election at the Annual Meeting on June 3, 2026.
The company highlighted Dr. DeFord's contributions during the merger with NuVasive and his service on the Nominating and Governance Committee. The chairman thanked him for his service, and Dr. DeFord expressed appreciation for serving during the company's growth in musculoskeletal technology.
Globus Medical (NYSE: GMED) reported strong Q4 and full‑year 2025 results with Q4 net sales $826.4M (+25.7% as‑reported) and FY2025 net sales $2,938.9M (+16.7%). GAAP diluted EPS was $1.03 in Q4 and $3.92 for FY2025; non‑GAAP diluted EPS was $1.28 Q4 and $3.98 FY2025.
The company cited integration benefits from Nevro and NuVasive, margin expansion, and reaffirmed 2026 revenue guidance of $3.18–$3.22B while updating non‑GAAP EPS guidance to $4.40–$4.50.
Globus Medical (NYSE:GMED) will announce fourth-quarter and full-year 2025 financial results after market close on February 24, 2026. The company will host a teleconference and live webcast at 4:30 p.m. Eastern Time the same day.
Investors can access the live webcast and audio archive on the Globus Medical Investors page. Telephone participation requires advance registration to receive a dial-in number, unique passcode, and registrant ID.
Globus Medical (NYSE: GMED) reported preliminary unaudited sales for Q4 and full year 2025. Q4 2025 sales are estimated at $823.2M, up 25.2% year-over-year on an as-reported basis. Full year 2025 sales are estimated at $2.936B, up 16.5% year-over-year. Excluding Nevro, Globus base business Q4 revenue was $723.3M, up 10.0% year-over-year, led by US Spine. The company issued 2026 revenue guidance of $3.18B–$3.22B and non-GAAP EPS guidance of $4.30–$4.40. Final audited results are expected on Feb 24, 2026.
Globus Medical (NYSE: GMED) reported third quarter 2025 results: worldwide net sales $769.0M (+22.9% / +22.3% constant currency) and GAAP net income $119.0M (+129.5%). GAAP diluted EPS was $0.88 and non-GAAP diluted EPS was $1.18 (+42.6%).
Quarter highlights include U.S. sales +24.6%, international sales +16.5% (13.5% CC), record non-GAAP free cash flow $213.9M (up 24% QoQ), net cash from operations $249.7M, and $40M of share repurchases in Q3 (total repurchases $255.5M YTD).
The company raised 2025 guidance to $2.86–$2.90B revenue and $3.75–$3.85 non-GAAP EPS; Nevro is expected to be accretive in 2025.
Globus Medical (NYSE:GMED) will announce third quarter results for the period ended September 30, 2025 after market close on Thursday, November 6, 2025. A copy of the release will be available on the company Investors website.
After the release, Globus Medical will host a teleconference and live webcast at 4:30 p.m. Eastern Time for the investment community. Telephone participants must register in advance to receive dial-in details, a unique passcode, and registrant ID. An audio archive will be posted on the Investors page after the call.
Globus Medical (NYSE: GMED) launched the ANTHEM™ Elbow Fracture System on October 14, 2025, a comprehensive plating portfolio for a wide spectrum of elbow fractures.
The system includes 14 plate families, 2.7mm and 3.5mm screw options, anatomy-specific reduction instruments, and polyaxial locking holes that permit fixed-angle or 40º cone angulation for flexible fixation. Devices target distal humerus, proximal ulna, proximal radius, and coronoid fractures and are designed to simplify surgical workflow for complex patterns.
Globus Medical (NYSE: GMED) has secured a favorable jury verdict in a patent infringement case against Life Spine, Inc. in Delaware. The jury found that Life Spine's Prolift implants infringed on Globus Medical's patent for expandable spinal fusion implants, awarding both lost profits and reasonable royalty damages.
The company, led by CEO Keith Pfeil, also has a separate ongoing patent litigation against Alphatec, Inc. regarding expandable implant and retractor technology. The verdict reinforces Globus Medical's position as a leading innovator in musculoskeletal technology, particularly in expandable implant technologies that improve spinal surgery outcomes.